Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose posttransplant cyclophosphamide plus low-dose ATG vs standard-dose ATG for GVHD prophylaxis in haploidentical PBSCT
ChiCTR2200058591Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Mar 2018
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cyclophosphamide and antithymocyte globulin rabbit in hematopoietic malignancies, leukemia, lymphoma and 1 more (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Incidence of grade II-IV acute graft-versus-host disease. Started Mar 2018; status: recruiting.
02
Drugs
cyclophosphamideantithymocyte globulin rabbit
03
Conditions
hematopoietic malignanciesleukemialymphomamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2200058591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058591.